$BRTX
BioRestorative Therapies, Inc. Stock $brtx

$brtx Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000114420414067818 Filed on November 13, 2014

Income Statement

Concept	2014 Q4	2014 Q3
Revenue	$80.00K	$159.9K
YoY Change		127844.0%
Cost Of Revenue	$110.0K	$66.12K
YoY Change		661050.0%
Gross Profit	-$30.00K	$93.82K
YoY Change		81478.26%
Gross Profit Margin	-37.5%	58.66%
Selling, General & Admin	$940.0K	$700.0K
YoY Change
% of Gross Profit		746.15%
Research & Development	$350.0K	$290.7K
YoY Change		-29.94%
% of Gross Profit		309.87%
Depreciation & Amortization	$30.00K	$20.00K
YoY Change
% of Gross Profit		21.32%
Operating Expenses	$1.290M	$989.8K
YoY Change		-12.34%
Operating Profit	-$1.320M	-$896.0K
YoY Change		-20.64%
Interest Expense	-$150.0K	$74.78K
YoY Change		33.45%
% of Operating Profit
Other Income/Expense, Net	-$20.00K	-$204.4K
YoY Change		17.49%
Pretax Income	-$1.480M	-$1.100M
YoY Change
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.480M	-$1.100M
YoY Change		-15.55%
Net Earnings / Revenue	-1850.0%	-688.08%
Basic Earnings Per Share
Diluted Earnings Per Share	-$925.0K	-$814.8K
COMMON SHARES
Basic Shares Outstanding	31.46M shares	26.80M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q4	2014 Q3	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$90.00K	$370.0K
YoY Change
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets	$20.00K	$30.00K
YoY Change
Inventory	$1.945K	$17.39K	$17.97K
Prepaid Expenses
Receivables	$0.00	$0.00
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$114.3K	$421.5K	$239.8K
YoY Change	-52.33%		666.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$493.9K	$73.58K	$35.57K
YoY Change	1288.48%		-40.13%
Goodwill
YoY Change
Intangibles	$1.038M	$1.055M	$1.108M
YoY Change	-6.3%		-5.93%
Long-Term Investments
YoY Change
Other Assets	$50.00K	$50.00K
YoY Change
Total Long-Term Assets	$1.577M	$1.175M	$1.143M
YoY Change	38.0%		-7.57%
TOTAL ASSETS
Total Short-Term Assets	$114.3K	$421.5K	$239.8K
Total Long-Term Assets	$1.577M	$1.175M	$1.143M
Total Assets	$1.692M	$1.596M	$1.383M
YoY Change	22.34%		9.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.112M	$774.1K	$1.270M
YoY Change	-12.45%		64.63%
Accrued Expenses	$1.467M	$1.220M	$1.177M
YoY Change	24.63%		19.07%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.690M	$5.170M
YoY Change
Total Short-Term Liabilities	$8.525M	$7.428M	$7.503M
YoY Change	13.63%		166.43%
LONG-TERM LIABILITIES
Long-Term Debt	$50.00K	$620.0K
YoY Change
Other Long-Term Liabilities	$10.00K	$0.00
YoY Change
Total Long-Term Liabilities	$60.00K	$620.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.525M	$7.428M	$7.503M
Total Long-Term Liabilities	$60.00K	$620.0K
Total Liabilities	$8.580M	$8.054M	$8.068M
YoY Change	6.35%		25.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$25.40M		-$19.81M
YoY Change	28.2%
Common Stock	$1.726K	$31.58K	$19.63K
YoY Change	-91.21%		27.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$32.00K	$32.00K	$32.00K
YoY Change	0.0%		0.0%
Treasury Stock Shares	27.93K shares	558.6K shares	558.6K shares
Shareholders Equity	-$6.888M	-$6.458M	-$6.685M
YoY Change
Total Liabilities & Shareholders Equity	$1.692M	$1.596M	$1.383M
YoY Change	22.34%		9.06%

Cashflow Statement

Concept	2014 Q4	2014 Q3
OPERATING ACTIVITIES
Net Income	-$1.480M	-$1.100M
YoY Change		-15.55%
Depreciation, Depletion And Amortization	$30.00K	$20.00K
YoY Change
Cash From Operating Activities	-$640.0K	-$830.0K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures	-$170.0K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$170.0K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	520.0K	1.150M
YoY Change
NET CHANGE
Cash From Operating Activities	-640.0K	-830.0K
Cash From Investing Activities	-170.0K	0.000
Cash From Financing Activities	520.0K	1.150M
Net Change In Cash	-290.0K	320.0K
YoY Change
FREE CASH FLOW
Cash From Operating Activities	-$640.0K	-$830.0K
Capital Expenditures	-$170.0K	$0.00
Free Cash Flow	-$470.0K	-$830.0K
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1055186	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1107545	USD
CY2014Q3	us-gaap	Assets Assets	1596176	USD
CY2014Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1220282	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1176662	USD
CY2014Q3	us-gaap	Cash Cash	373970	USD
CY2013Q4	us-gaap	Cash Cash	201098	USD
CY2014Q3	us-gaap	Inventory Net InventoryNet	17385	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	17965	USD
CY2014Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	30160	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20739	USD
CY2014Q3	us-gaap	Assets Current AssetsCurrent	421515	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	239802	USD
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	73575	USD
CY2014Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	107308	USD
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	65909	USD
CY2014Q3	us-gaap	Notes Payable Current NotesPayableCurrent	5171355	USD
CY2013Q4	us-gaap	Notes Payable Current NotesPayableCurrent	4990009	USD
CY2014Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	154662	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	7427661	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7502550	USD
CY2014Q3	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	3955	USD
CY2014Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	774054	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1269970	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	41434	USD
CY2014Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	622685	USD
CY2013Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	524000	USD
CY2014Q3	us-gaap	Liabilities Liabilities	8054301	USD
CY2013Q4	us-gaap	Liabilities Liabilities	8067984	USD
CY2014Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	31578	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	19633	USD
CY2014Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17457980	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	13139712	USD
CY2014Q3	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	23915683	USD
CY2013Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	19812414	USD
CY2014Q3	us-gaap	Treasury Stock Value TreasuryStockValue	32000	USD
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	32000	USD
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	-6458125	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-6685069	USD
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1596176	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1382915	USD
CY2014Q3	brtx	Working Capital Net WorkingCapitalNet	7006146	USD
	brtx	Proceeds From Equity Financing ProceedsFromEquityFinancing	50000	USD
CY2014Q3	brtx	Notes Payable Aggregate Principal Past Due NotesPayableAggregatePrincipalPastDue	344063	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35568	USD
CY2013Q4	us-gaap	Assets Assets	1382915	USD
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	89063	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	139063	USD
CY2014Q3	us-gaap	Other Notes Payable OtherNotesPayable	392685	USD
CY2014Q3	brtx	Debt Instrument Outstanding Face Amount Percentage DebtInstrumentOutstandingFaceAmountPercentage	0.77	pure
CY2014Q1	us-gaap	Debt Instrument Payment Terms DebtInstrumentPaymentTerms	Payment terms are (1) $150,000 at commencement; (2) $50,000 upon achievement of a specified deliverable; and (3) $50,000 upon achievement of the final specified deliverable.
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8608890	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16617108	shares
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	35539	USD
CY2013	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	24990	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	60529	USD
CY2014Q3	brtx	Credit Card Payable Current CreditCardPayableCurrent	4163	USD
CY2013Q4	brtx	Credit Card Payable Current CreditCardPayableCurrent	6000	USD
CY2014Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	796666	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	672535	USD
CY2014Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	419453	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	495817	USD
CY2014Q3	us-gaap	Accrued Rent Current AccruedRentCurrent	0	USD
CY2013Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	2310	USD
CY2014Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.12	pure
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-49094	USD
CY2014Q3	brtx	Common Stock Aggregate Grant Date Fair Value CommonStockAggregateGrantDateFairValue	330436	USD
CY2014Q2	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	30000	USD
CY2014Q3	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	1062500	USD
CY2014Q2	brtx	Debt Instrument Issued For Consideration DebtInstrumentIssuedForConsideration	25000	USD
	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	15000	USD
CY2014Q2	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	5000	USD
	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	80000	USD
CY2014Q2	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	145000	USD
	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	86563	USD
CY2014Q2	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	145000	USD
CY2014Q3	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	45179	USD
	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	35000	USD
CY2014Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.79	pure
CY2014Q3	brtx	Payments Under Research And Development Agreements PaymentsUnderResearchAndDevelopmentAgreements	53000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	11219	shares
	brtx	Stock Issued During Period Value Issued In Exchange Of Notes Payable Principal Amount StockIssuedDuringPeriodValueIssuedInExchangeOfNotesPayablePrincipalAmount	274000	USD
	brtx	Stock Issued During Period Value Issued In Exchange Of Notes Payable Interest Amount StockIssuedDuringPeriodValueIssuedInExchangeOfNotesPayableInterestAmount	19932	USD
	brtx	Stock Issued During Period Shares Issued In Exchange Of Notes Payable StockIssuedDuringPeriodSharesIssuedInExchangeOfNotesPayable	1101453	shares
	brtx	Warrants Issued During Period Number Of Warrants WarrantsIssuedDuringPeriodNumberOfWarrants	100000	shares
CY2014Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.75
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0.75	USD
	brtx	Debt Instrument Issue Description DebtInstrumentIssueDescription	(a) 55%-60%, depending on the particular note, of the fair value of the Company’s stock or (b) $0.05 per share. The remaining $30,000 is convertible into shares of the Company’s common stock at the election of the holder any time after September 10, 2014 at the lesser of (a) $0.50 per share or (b) 65% of the fair value of the Company’s common stock, but with a floor of $0.05 per share.
CY2014Q3	brtx	Warrant Aggregate Grant Date Fair Value WarrantAggregateGrantDateFairValue	12590	USD
	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2014-01-08
	us-gaap	Debt Instrument Interest Rate Stated Percentage Rate Range Minimum DebtInstrumentInterestRateStatedPercentageRateRangeMinimum	0.08	pure
	us-gaap	Debt Instrument Interest Rate Stated Percentage Rate Range Maximum DebtInstrumentInterestRateStatedPercentageRateRangeMaximum	0.15	pure
	us-gaap	Debt Instrument Increase Decrease Other Net DebtInstrumentIncreaseDecreaseOtherNet	73058	USD
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	100000	shares
CY2014Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	90000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1.75	pure
CY2013Q4	us-gaap	Notes Payable NotesPayable	5514009	USD
	brtx	Proceeds From Issuance Of Notes Payable ProceedsFromIssuanceOfNotesPayable	675000	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.31
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.83
CY2014Q1	brtx	Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue	5860	USD
CY2014Q3	brtx	Debt Instrument Unamortized Debt Discount Noncurrent Portion DebtInstrumentUnamortizedDebtDiscountNoncurrentPortion	0	USD
CY2013Q4	brtx	Debt Instrument Unamortized Debt Discount Noncurrent Portion DebtInstrumentUnamortizedDebtDiscountNoncurrentPortion	3110	USD
CY2014Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
	brtx	Exchanges For Equity ExchangesForEquity	-274000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	76000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	17000	USD
CY2013Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	23000	USD
CY2014Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	3000	USD
CY2014Q3	brtx	Debt Instrument Unamortized Debt Discount Current Portion DebtInstrumentUnamortizedDebtDiscountCurrentPortion	76518	USD
CY2013Q4	brtx	Debt Instrument Unamortized Debt Discount Current Portion DebtInstrumentUnamortizedDebtDiscountCurrentPortion	237381	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	312500	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	53000	USD
	brtx	Set Up Of Debt Discount SetUpOfDebtDiscount	-227563	USD
	brtx	Accretion Of Interest Expense AccretionOfInterestExpense	97992	USD
CY2014Q3	us-gaap	Notes Payable NotesPayable	5794040	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P3Y
CY2014Q1	brtx	Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue	67830	USD
CY2013Q4	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	193000	USD
CY2013Q4	brtx	Loss Contingency Damages Paid Value Warrants Issued LossContingencyDamagesPaidValueWarrantsIssued	80000	shares
CY2014Q2	brtx	Compensation Paid To Directors Aggregate Amount CompensationPaidToDirectorsAggregateAmount	30000	USD
CY2014Q2	brtx	Compensation Paid To Directors Instalment Amount CompensationPaidToDirectorsInstalmentAmount	50000	USD
CY2014Q2	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	80000	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	831669	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.58
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.24
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.48
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.27
CY2014Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31577549	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19633173	shares
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31018928	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19074552	shares
CY2014Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	558621	shares
CY2013Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	558621	shares
CY2014Q3	brtx	Share Based Compensation Exercise Price Range Number Of Outstanding Warrants ShareBasedCompensationExercisePriceRangeNumberOfOutstandingWarrants	7408683	shares
	brtx	Share Based Compensations Exercise Price Range Exercisable Warrant Weighted Average Remaining Contractual Term ShareBasedCompensationsExercisePriceRangeExercisableWarrantWeightedAverageRemainingContractualTerm	P3Y3M18D
CY2014Q3	brtx	Share Based Compensation Exercise Price Range Number Of Exercisable Warrants ShareBasedCompensationExercisePriceRangeNumberOfExercisableWarrants	6708683	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5043000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3775000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	34000	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8784000	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5473167	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.03
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.55
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.97
	brtx	Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y9M18D
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	60000	USD
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	13000	USD
CY2014Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	8784000	shares
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P7Y9M18D
CY2014Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	5473167	shares
	us-gaap	Revenues Revenues	1680	USD
	us-gaap	Revenues Revenues	336246	USD
CY2013Q3	us-gaap	Revenues Revenues	125	USD
CY2014Q3	us-gaap	Revenues Revenues	159930	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	208	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	108541	USD
CY2013Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	10	USD
CY2014Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	66115	USD
	us-gaap	Gross Profit GrossProfit	1472	USD
	us-gaap	Gross Profit GrossProfit	227705	USD
CY2013Q3	us-gaap	Gross Profit GrossProfit	115	USD
CY2014Q3	us-gaap	Gross Profit GrossProfit	93815	USD
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	82983	USD
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	89169	USD
CY2013Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	17391	USD
CY2014Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	41840	USD
	us-gaap	Professional Fees ProfessionalFees	553404	USD
	us-gaap	Professional Fees ProfessionalFees	979255	USD
CY2013Q3	us-gaap	Professional Fees ProfessionalFees	182899	USD
CY2014Q3	us-gaap	Professional Fees ProfessionalFees	154492	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1188276	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1077778	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	414918	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	290707	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1719270	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1687415	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	513909	USD
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	502783	USD
	us-gaap	Operating Expenses OperatingExpenses	3543933	USD
	us-gaap	Operating Expenses OperatingExpenses	3833617	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	1129117	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	989822	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3542461	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3605912	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1129002	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-896007	USD
	us-gaap	Interest Expense InterestExpense	285939	USD
	us-gaap	Interest Expense InterestExpense	220301	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	56036	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	74780	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	284601	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	381602	USD
CY2013Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	117970	USD
CY2014Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	137167	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7200	USD
CY2013Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2014Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	brtx	Warrant Modification Expense WarrantModificationExpense	0	USD
	brtx	Adjustments To Additional Paid In Capital Warrant Modification AdjustmentsToAdditionalPaidInCapitalWarrantModification	30128	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	816112	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	79064	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	73889	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	brtx	Warrant Modification Expense WarrantModificationExpense	-30128	USD
CY2013Q3	brtx	Warrant Modification Expense WarrantModificationExpense	0	USD
CY2014Q3	brtx	Warrant Modification Expense WarrantModificationExpense	0	USD
	brtx	Gain Loss Related To Settlement Of Note And Payables GainLossRelatedToSettlementOfNoteAndPayables	0	USD
	brtx	Gain Loss Related To Settlement Of Note And Payables GainLossRelatedToSettlementOfNoteAndPayables	183768	USD
CY2013Q3	brtx	Gain Loss Related To Settlement Of Note And Payables GainLossRelatedToSettlementOfNoteAndPayables	0	USD
CY2014Q3	brtx	Gain Loss Related To Settlement Of Note And Payables GainLossRelatedToSettlementOfNoteAndPayables	7500	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-577740	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-497357	USD
CY2013Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-174006	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-204447	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4120201	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4103269	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-1303008	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-1100454	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16255317	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23402779	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16937376	shares
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27043758	shares
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	80000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	327946	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1009	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	582061	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1075499	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5481	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-580	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	29273	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-11629	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	384843	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-488416	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	908535	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	449668	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	154662	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	2211550	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1509676	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1908651	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2593593	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	980	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-546	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	979000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	670000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	4000	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	119255	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	90325	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	brtx	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	905000	USD
	brtx	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	2095001	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1908930	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2767011	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	279	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	172872	USD
CY2012Q4	us-gaap	Cash Cash	363	USD
CY2013Q3	us-gaap	Cash Cash	642	USD
	us-gaap	Interest Paid InterestPaid	36925	USD
	us-gaap	Interest Paid InterestPaid	76060	USD
	brtx	Conversion Of Notes Payable And Accrued Interest In To Common Stock ConversionOfNotesPayableAndAccruedInterestInToCommonStock	0	USD
	brtx	Conversion Of Notes Payable And Accrued Interest In To Common Stock ConversionOfNotesPayableAndAccruedInterestInToCommonStock	327946	USD
	brtx	Reclassification Of Accrued Interest In Connection With Note Payable Issuance ReclassificationOfAccruedInterestInConnectionWithNotePayableIssuance	68100	USD
	brtx	Reclassification Of Accrued Interest In Connection With Note Payable Issuance ReclassificationOfAccruedInterestInConnectionWithNotePayableIssuance	73058	USD
	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	0	USD
CY2014Q3	us-gaap	Security Deposit SecurityDeposit	45900	USD
CY2013Q4	us-gaap	Security Deposit SecurityDeposit	0	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	BioRestorative Therapies, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001505497
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	BRTX
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	31457869	shares
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1526	USD
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	0	USD
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	45900	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	89063	USD
CY2014Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	4000000	USD
CY2014Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	7500	USD
CY2014Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	550000	shares
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	30000	USD
	us-gaap	Debt Instrument Maturity Date Range Start1 DebtInstrumentMaturityDateRangeStart1	2014-07-31
	us-gaap	Debt Instrument Maturity Date Range End1 DebtInstrumentMaturityDateRangeEnd1	2014-12-31
	brtx	Settlement Of Accreted Interest SettlementOfAccretedInterest	-7500	USD
	brtx	Proceeds From Issuance Of Common Stock And Warrants Net One ProceedsFromIssuanceOfCommonStockAndWarrantsNetOne	10000	USD
CY2014Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	10000	shares
	brtx	Class Of Warrant Or Right Aggregate Expense Or Revenue Recognized ClassOfWarrantOrRightAggregateExpenseOrRevenueRecognized	1500	USD
	brtx	Proceeds From Debt Financing ProceedsFromDebtFinancing	75000	USD

Files In Submission

Name	View Source	Status
0001144204-14-067818-index-headers.html	Edgar Link	pending
0001144204-14-067818-index.html	Edgar Link	pending
0001144204-14-067818.txt	Edgar Link	pending
0001144204-14-067818-xbrl.zip	Edgar Link	pending
brtx-20140930.xml	Edgar Link	completed
brtx-20140930.xsd	Edgar Link	pending
brtx-20140930_cal.xml	Edgar Link	unprocessable
brtx-20140930_def.xml	Edgar Link	unprocessable
brtx-20140930_lab.xml	Edgar Link	unprocessable
brtx-20140930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v393110_10q.htm	Edgar Link	pending
v393110_ex31-1.htm	Edgar Link	pending
v393110_ex31-2.htm	Edgar Link	pending
v393110_ex32.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BRTX
BioRestorative Therapies, Inc. Stock $brtx

2014 Q4 Form 10-Q Financial Statement

#000114420414067818 Filed on November 13, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRTX BioRestorative Therapies, Inc. Stock $brtx

2014 Q4 Form 10-Q Financial Statement

#000114420414067818 Filed on November 13, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRTX
BioRestorative Therapies, Inc. Stock $brtx